Yifan Pharmaceutical: Recombinant Human Growth Hormone Injection Receives Approval for Clinical Trials.

Yifan Pharmaceuticals announced that its wholly-owned subsidiary Yifan Pharmaceuticals Co., Ltd. recently received the Approval Notice for Drug Clinical Trial issued by the National Medical Products Administration. The drug is called Human Somatropin Injection, with a dosage form of injection, and is classified as a therapeutic biological product category 3.3. According to the Drug Administration Law of the People's Republic of China and related regulations, after review, it is approved to carry out clinical trials in accordance with the requirements for biosimilar drugs. Human Somatropin Injection is a biosimilar drug developed by the company as a recombinant human growth hormone injection from Novo Nordisk. It has the same amino acid sequence as natural human growth hormones and is currently a mainstream therapy for growth hormone deficiency.